Resurgence of pertussis calls for re-evaluation of pertussis animal models

Expert Review of Vaccines

Volumn 11, Issue 9, 2012, Pages 1121-1137

  Van Der Ark, Arno A J ^a   Hozbor, Daniela F ^b   Boog, Claire J P ^a   Metz, Bernard ^a   Van Den Dobbelsteen, Germie P J M ^a,c   Van Els, Cécile A C M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^c Innovation and Discovery Lab   (Netherlands)

Author keywords

animal models; disease and pathogen; immune modulation; pathogen adaptation; re emerging pertussis; vaccine effectiveness; virulence

Indexed keywords

FIMBRIA PROTEIN; GAMMA INTERFERON; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; RANTES;

ADAPTATION; ANIMAL MODEL; B LYMPHOCYTE; BACTERIAL COLONIZATION; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM ADHERENCE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG EFFICACY; DRUG QUALITY; DRUG RESEARCH; EPIDEMIOLOGICAL DATA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; MEMORY CELL; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROTECTION; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION;

ANIMALS; BORDETELLA PERTUSSIS; COMMUNICABLE DISEASES, EMERGING; HUMANS; MODELS, ANIMAL; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 84869448132     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.83     Document Type: Review

References (134)

1. WHO. Pertussis vaccines: WHO position paper. Wkly Epidemiol. Rec. 85(40), 385-400 (2010
2. Halperin S, De Serres, G. Pertussis. In: Bacterial Infections of Humans. Brachman PS, Elias A (Eds). Springer, NY, USA, 577-595 (2009
3. Yih WK, Silva EA, Ida J, Harrington N, Lett SM, George H. Bordetella holmesii-like organisms isolated from Massachusetts patients with pertussis-like symptoms. Emerging Infect. Dis. 5(3), 441-443 (1999
4. Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA, Mooi FR. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. Plos Pathog. 1(4), e45 (2005
5. Locht C. Molecular aspects of Bordetella pertussis pathogenesis. Int. Microbiol. 2(3), 137-144 (1999
6. Merkel TJ, Boucher PE, Stibitz S, Grippe VK. Analysis of bvgR expression in Bordetella pertussis. J. Bacteriol. 185(23), 6902-6912 (2003
7. King AJ, van Gorkom T, van der Heide HG, Advani A, van der Lee S. Changes in the genomic content of circulating Bordetella pertussis strains isolated from The Netherlands, Sweden, Japan and Australia: Adaptive evolution or drift? BMC Genomics 11, 64 (2010
8. Bart MJ, van Gent M, van der Heide HG et al. Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics 11, 627 (2010
9. Mooi FR. Bordetella pertussis and vaccination: The persistence of a genetically monomorphic pathogen. Infect. Genet. Evol. 10(1), 36-49 (2010
10. Canthaboo C, Xing D, Douglas A, Corbel M. Investigation of an aerosol challenge model as alternative to the intracerebral mouse protection test for potency assay of whole cell pertussis vaccines. Biologicals 28(4), 241-246 (2000
11. Mills KH. Immunity to Bordetella pertussis. Microbes Infect. 3(8), 655-677 (2001
12. van der Ark A, van Straaten-van de Kappelle I, Hendriksen C, van de Donk H. Pertussis serological potency test as an alternatively to the intracerebral mouse protection test. Dev. Biol. Stand. 86, 271-281 (1996
13. Ausiello CM, Lande R, Urbani F et al. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect. Immun. 67(8), 4064-4071 (1999
14. Hendrikx LH, Schure RM, Oztürk K et al. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. Vaccine 29(40), 6874-6880 (2011
15. Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 25(2), 391-398 (2007
16. Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur. J. Pediatr. 161(3), 142-146 (2002
17. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24(SUPPL5), S58-S61 (2005
18. Kendrick PL, Eldering G. Mouse protection tests in the study of pertussis vaccine; a comparative series using the intracerebral route for challenge. Am. J. Public Health Nations. Health 37(7), 803-810 (1947
19. Gaines-Das R, Horiuchi Y, Zhang SM et al. Modified intra-cerebral challenge assay for acellular pertussis vaccines: Comparisons among whole cell and acellular vaccines. Vaccine 27(49), 6824-6832 (2009
20. André M, Poirier B, Bornstein N, Marmonier D, El Zaouk A, Fuchs F. Key points for the development of mouse immunogenicity test as potency assay for acellular pertussis vaccines. Biologicals 28(4), 217-225 (2000
21. Mastrantonio P, Spigaglia P, van Oirschot H et al. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology (Reading, Engl.) 145(PT8), 2069-2075 (1999
22. Guiso N, Capiau C, Carletti G, Poolman J, Hauser P. Intranasal murine model of Bordetella pertussis infection I Prediction of protection in human infants by acellular vaccines. Vaccine 17(19), 2366-2376 (1999
23. Mills KH, Brady M, Ryan E, Mahon BP. A respiratory challenge model for infection with Bordetella pertussis: Application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity. Dev. Biol. Stand. 95, 31-41 (1998
24. Mills KH, Ryan M, Ryan E, Mahon BP. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66(2), 594-602 (1998
25. Taranger J, Trollfors B, Bergfors E et al. Mass vaccination of children with pertussis toxoid- Decreased incidence in both vaccinated and nonvaccinated persons. Clin. Infect. Dis. 33(7), 1004-1010 (2001
26. Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand. J. Infect. Dis. 43(9), 683-689 (2011
27. Rashid H, Khandaker G, Booy R. Vaccination and herd immunity: What more do we know? Curr. Opin. Infect. Dis. 25(3), 243-249 (2012
28. Hewlett EL, Edwards KM. Clinical practice. Pertussis- not just for kids. N. Engl. J. Med. 352(12), 1215-1222 (2005
29. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr. Infect. Dis. J. 24(SUPPL5), S10-S18 (2005
30. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J. Clin. Microbiol. 43(6), 2856-2865 (2005
31. Hozbor D, Mooi F, Flores D et al. Pertussis epidemiology in Argentina: Trends over 2004-2007. J. Infect. 59(4), 225-231 (2009
32. van Amersfoorth SC, Schouls LM, van der Heide HG et al. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J. Clin. Microbiol. 43(6), 2837-2843 (2005
33. Octavia S, Sintchenko V, Gilbert GL et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J. Infect. Dis. 205(8), 1220-1224 (2012
34. Peppler MS, Kuny S, Nevesinjac A et al. Strain variation among Bordetella pertussis isolates from Québec and Alberta provinces of Canada from 1985 to 1994. J. Clin. Microbiol. 41(7), 3344-3347 (2003
35. Aguas R, Gonçalves G, Gomes MG. Pertussis: Increasing disease as a consequence of reducing transmission. Lancet Infect. Dis. 6(2), 112-117 (2006
36. Bamberger ES, Srugo I. What is new in pertussis? Eur. J. Pediatr. 167(2), 133-139 (2008
37. Packard ER, Parton R, Coote JG, Fry NK. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J. Med. Microbiol. 53(PT5), 355-365 (2004
38. van Boven M, Mooi FR, Schellekens JF, de Melker HE, Kretzschmar M. Pathogen adaptation under imperfect vaccination: Implications for pertussis. Proc. Biol. Sci. 272(1572), 1617-1624 (2005
39. Hallander H, Advani A, Riffelmann M et al. Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J. Clin. Microbiol. 45(10), 3257-3262 (2007
40. He Q, Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol. 3(3), 329-339 (2008
41. Mooi FR, van Loo IH, van Gent M et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerging Infect. Dis. 15(8), 1206-1213 (2009
42. Van Loo IH, Mooi FR. Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology (Reading, Engl.) 148(PT7), 2011-2018 (2002
43. Godfroid F, Denoël P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expert Rev. Vaccines 4(5), 757-778 (2005
44. Kallonen T, He Q. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev. Vaccines 8(7), 863-875 (2009
45. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 27(43), 6034-6041 (2009
46. Njamkepo E, Cantinelli T, Guigon G, Guiso N. Genomic analysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas. Microbes Infect. 10(14-15), 1582-1586 (2008
47. Otsuka N, Han HJ, Toyoizumi-Ajisaka H et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. Plos One 7(2), e31985 (2012
48. Plotkin SA. Vaccines: Correlates of vaccine-induced immunity. Clin. Infect. Dis. 47(3), 401-409 (2008
49. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 118(3), 978-984 (2006
50. Olin P, Hallander HO, Gustafsson L, Reizenstein E, Storsaeter J. How to make sense of pertussis immunogenicity data. Clin. Infect. Dis. 33(SUPPL4), S288-S291 (2001
51. Pebody RG, Gay NJ, Giammanco A et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol. Infect. 133(1), 159-171 (2005
52. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16(20), 1907-1916 (1998
53. Hendrikx LH, Öztürk K, de Rond LG et al. Serum IgA responses against pertussis proteins in infected and Dutch wP or aP vaccinated children: An additional role in pertussis diagnostics. Plos One 6(11), e27681 (2011
54. Leef M, Elkins KL, Barbic J, Shahin RD. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J. Exp. Med. 191(11), 1841-1852 (2000
55. Mahon BP, Brady MT, Mills KH. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: Implications for long-term immunity in children. J. Infect. Dis. 181(6), 2087-2091 (2000
56. Buisman AM, de Rond CG, Oztürk K, Ten Hulscher HI, van Binnendijk RS. Long-term presence of memory B-cells specific for different vaccine components. Vaccine 28(1), 179-186 (2009
57. Hendrikx LH, Oztürk K, de Rond LG et al. Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins. Vaccine 29(7), 1431-1437 (2011
58. Stenger RM, Smits M, Kuipers B et al. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory. Vaccine 28(40), 6637-6646 (2010
59. Stenger RM, Smits M, Kuipers B, Kessen SF, Boog CJ, van Els CA. Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens. Clin. Vaccine Immunol. 18(4), 595-603 (2011
60. Ausiello CM, Urbani F, la Sala A, Lande R, Cassone A. Vaccine- And antigendependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65(6), 2168-2174 (1997
61. Mascart F, Verscheure V, Malfroot A et al. Bordetella pertussis infection in 2-monthold infants promotes type 1 T cell responses. J. Immunol. 170(3), 1504-1509 (2003
62. Ryan M, Murphy G, Ryan E et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93(1), 1-10 (1998
63. Vermeulen F, Verscheure V, Damis E et al. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin. Vaccine Immunol. 17(2), 258-262 (2010
64. White OJ, Rowe J, Richmond P et al. Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine 28(14), 2648-2652 (2010
65. Nilsson L, Kjellman NI, Björkstén B. A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Arch. Pediatr. Adolesc. Med. 152(8), 734-738 (1998
66. Ryan EJ, Nilsson L, Kjellman N, Gothefors L, Mills KH. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. Clin. Exp. Immunol. 121(2), 193-200 (2000
67. White OJ, McKenna KL, Bosco A, H J van den Biggelaar A, Richmond P, Holt PG. A genomics-based approach to assessment of vaccine safety and immunogenicity in children. Vaccine 30(10), 1865-1874 (2012
68. Rowe J, Yerkovich ST, Richmond P et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect. Immun. 73(12), 8130-8135 (2005
69. Scheifele DW, Ochnio JJ, Halperin SA. Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens. Pediatr. Infect. Dis. J. 28(11), 985-989 (2009
70. Andreasen C, Carbonetti NH. Role of neutrophils in response to Bordetella pertussis infection in mice. Infect. Immun. 77(3), 1182-1188 (2009
71. Banus S, Stenger RM, Gremmer ER et al. The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol. 9, 21 (2008
72. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: Role of IL-17-producing T cells. J. Immunol. 177(11), 7980-7989 (2006
73. Fedele G, Bianco M, Debrie AS, Locht C, Ausiello CM. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J. Immunol. 186(9), 5388-5396 (2011
74. Stenger RM, Poelen MC, Moret EE et al. Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect. Immun. 77(2), 896-903 (2009
75. Panum Pl. Boebachtungen uber das maserncontagium. Vichows Archives 1847(1), 492-503.
76. Paul JR, Riordan JT, Melnick JL. Antibodies to three different antigenic types of poliomyelitis virus in sera from North Alaskan Eskimos. Am. J. Hyg. 54(2), 275-285 (1951
77. Sawyer WA. Persistence of yellow fever immunity. J. Prevent. Med. 5, 413-428 (1930
78. De Greeff SC, de Melker HE, van Gageldonk PG et al. Seroprevalence of pertussis in The Netherlands: Evidence for increased circulation of Bordetella pertussis. Plos One 5(12), e14183 (2010
79. Greco D, Salmaso S, Mastrantonio P et al. A controlled trial of two acellular vaccines and One whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334(6), 341-348 (1996
80. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334(6), 349-355 (1996
81. Hendrikx LH, de Rond LG, Oztürk K et al. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age. Vaccine 29(34), 5725-5730 (2011
82. Simondon F, Yam A, Gagnepain JY, Wassilak S, Danve B, Cadoz M. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants. Eur. J. Clin. Microbiol. Infect. Dis. 15(12), 927-932 (1996
83. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21(25-26), 3542-3549 (2003
84. Hendrikx LH, Felderhof MK, Oztürk K et al. Enhanced memory B-cell immune responses after a second acellular pertussis booster vaccination in children 9 years of age. Vaccine 30(1), 51-58 (2011
85. Luijkx TA, van Gaans-van den Brink JA, van Dijken HH, van den Dobbelsteen GP, van Els CA. Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model. Clin. Vaccine Immunol. 15(10), 1598-1605 (2008
86. Smits K, Smet J, Van Twillert I et al. Evaluation of Bordetella pertussis-specific immune responses after infection or after different vaccination programs in the framework of the FP7 Child-INNOVAC program. Presented at: 9th International Bordetella Symposium, Baltimore, MD, USA, 30 September-3 October 2010.
87. Eskola J. Analysis of Haemophilus influenzae type B conjugate and diphtheria-tetanus-pertussis combination vaccines. J. Infect. Dis. 174(SUPPL3), S302-S305 (1996
88. McGuirk P, Mills KH. Direct antiinflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur. J. Immunol. 30(2), 415-422 (2000
89. McGuirk P, McCann C, Mills KH. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: A novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 195(2), 221-231 (2002
90. de Gouw D, Diavatopoulos DA, Bootsma HJ, Hermans PW, Mooi FR. Pertussis: A matter of immune modulation. FEMS Microbiol. Rev. 35(3), 441-474 (2011
91. Carbonetti NH. Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease. Curr. Opin. Pharmacol. 7(3), 272-278 (2007
92. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18(2), 326-382 (2005
93. Pichichero ME. Booster vaccinations: Can immunologic memory outpace disease pathogenesis? Pediatrics 124(6), 1633-1641 (2009
94. Hickey FB, Brereton CF, Mills KH. Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells. J. Leukoc. Biol. 84(1), 234-243 (2008
95. Corbel MJ, Xing DK. Toxicity and potency evaluation of pertussis vaccines. Expert Rev. Vaccines 3(1), 89-101 (2004
96. Elahi S, Holmstrom J, Gerdts V. The benefits of using diverse animal models for studying pertussis. Trends Microbiol. 15(10), 462-468 (2007
97. Culotta CS, Harvey DF, Gordon EF. Whooping-cough: II. Experimental study. J.Pediatr. 6, 743-752 (1935
98. Elahi S, Brownlie R, Korzeniowski J et al. Infection of newborn piglets with Bordetella pertussis: A new model for pertussis. Infect. Immun. 73(6), 3636-3645 (2005
99. Elahi S, Buchanan RM, Attah-Poku S, Townsend HG, Babiuk LA, Gerdts V. The host defense peptide β-defensin 1 confers protection against Bordetella pertussis in newborn piglets. Infect. Immun. 74(4), 2338-2352 (2006
100. Feunou PF, Kammoun H, Debrie AS, Mielcarek N, Locht C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 28(43), 7047-7053 (2010
101. Hall E, Parton R, Wardlaw AC. Cough production, leucocytosis and serology of rats infected intrabronchially with Bordetella pertussis. J. Med. Microbiol. 40(3), 205-213 (1994
102. Hall E, Parton R, Wardlaw AC. Differences in coughing and other responses to intrabronchial infection with Bordetella pertussis among strains of rats. Infect. Immun. 65(11), 4711-4717 (1997
103. Hall E, Parton R, Wardlaw AC. Responses to acellular pertussis vaccines and component antigens in a coughing-rat model of pertussis. Vaccine 16(17), 1595-1603 (1998
104. Hall E, Parton R, Wardlaw AC. Timecourse of infection and responses in a coughing rat model of pertussis. J. Med. Microbiol. 48(1), 95-98 (1999
105. Hamstra HJ, Kuipers B, Schijf-Evers D, Loggen HG, Poolman JT. The purification and protective capacity of Bordetella pertussis outer membrane proteins. Vaccine 13(8), 747-752 (1995
106. Huang CC, Chen PM, Kuo JK et al. Experimental whooping cough. N. Engl. J. Med. 266, 105-111 (1962
107. Komatsu E, Yamaguchi F, Abe A, Weiss AA, Watanabe M. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clin. Vaccine Immunol. 17(5), 807-812 (2010
108. Parton R, Hall E, Wardlaw AC. Responses to Bordetella pertussis mutant strains and to vaccination in the coughing rat model of pertussis. J. Med. Microbiol. 40(5), 307-312 (1994
109. Rich AR, Long PH, Brown JH, Bliss EA, Holt LE Jr. Experiments upon the cause of whooping cough. Science 76(1971), 330-331 (1932
110. Shibley GS, Hoelscher H. Studies on whooping cough: I. type-specific (s) and dissociation (R) forms of hemophilus pertussis. J. Exp. Med. 60(4), 403-418 (1934
111. Stanbridge TN, Preston NW. Experimental pertussis infection in the vaccinated and unvaccinated marmoset: Similarities to natural infection in the child. J. Clin. Pathol. 25(6), 551 (1972
112. van der Ark A, van Straaten-van de Kappelle I, Akkermans A, Hendriksen C, van de Donk H. Development of pertussis serological potency test. Serological assessment of antibody response induced by whole cell vaccine as an alternative to mouse protection in an intracerebral challenge model. Biologicals 22(3), 233-242 (1994
113. van der Ark A, van Straaten-van de Kappelle I, Olander RM et al. The Pertussis serological potency test. Collaborative study to evaluate replacement of the mouse protection test. Biologicals 28(2), 105-118 (2000
114. Caro V, Bouchez V, Guiso N. Is the Sequenced Bordetella pertussis strain Tohama I representative of the species? J. Clin. Microbiol. 46(6), 2125-2128 (2008
115. Fry NK, Duncan J, Vaghji L, George RC, Harrison TG. Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method. Eur. J. Clin. Microbiol. Infect. Dis. 29(9), 1183-1185 (2010
116. Gaillard ME, Bottero D, Castuma CE, Basile LA, Hozbor D. Laboratory adaptation of Bordetella pertussis is associated with the loss of type three secretion system functionality. Infect. Immun. 79(9), 3677-3682 (2011
117. Xing DK, Corbel MJ, Dobbelaer R, Knezevic I. WHO working group on standardisation and control of acellular pertussis vaccines-report of a meeting held on 16-17 March 2006, St. Albans, United Kingdom. Vaccine 25(15), 2749-2757 (2007
118. Van Der Ark A, Kuipers B, Van Amerongen G et al. Infection procedure determines disease and immunity induced by B. pertussis strain variants in the coughing rat model. (2010). Presented at: 9th International Bordetella Symposium, Baltimore, MD, USA, 30 September- 3 October 2010.
119. Fennelly NK, Sisti F, Higgins SC et al. Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect. Immun. 76(3), 1257-1266 (2008
120. Heikkinen E, Xing DK, Olander RM et al. Bordetella pertussis isolates in Finland: Serotype and fimbrial expression. BMC Microbiol. 8, 162 (2008
121. King AJ, van Gorkom T, Pennings JL et al. Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: Identification of genes absent from epidemic strains. BMC Genomics 9, 311 (2008
122. van Gent M, Bart MJ, van der Heide HG et al. SNP-based typing: A useful tool to study Bordetella pertussis populations. Plos One 6(5), e20340 (2011
123. Warfel JM, Beren J, Kelly VK, Lee G, Merkel TJ. Nonhuman primate model of pertussis. Infect. Immun. 80(4), 1530-1536 (2012
124. Berry MP, Graham CM, McNab FW et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466(7309), 973-977 (2010
125. Nakaya HI, Wrammert J, Lee EK et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12(8), 786-795 (2011
126. Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10(1), 116-125 (2009
127. Pulendran B. Learning immunology from the yellow fever vaccine: Innate immunity to systems vaccinology. Nat. Rev. Immunol. 9(10), 741-747 (2009
128. Feunou PF, Bertout J, Locht C. T- And B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. Plos One 5(4), e10178 (2010
129. Mielcarek N, Debrie AS, Mahieux S, Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin. Vaccine Immunol. 17(3), 317-324 (2010
130. Mielcarek N, Debrie AS, Raze D et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. Plos Pathog. 2(7), e65 (2006
131. Skerry CM, Mahon BP. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin. Vaccine Immunol. 18(2), 187-193 (2011
132. Asensio CJ, Gaillard ME, Moreno G et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 29(8), 1649-1656 (2011
133. Hozbor D, Rodriguez ME, Fernández J, Lagares A, Guiso N, Yantorno O. Release of outer membrane vesicles from Bordetella pertussis. Curr. Microbiol. 38(5), 273-278 (1999
134. Roberts R, Moreno G, Bottero D et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 26(36), 4639-4646 (2008